I believe LLY has dumped it's own Tabalumab for RA and is proceeding with INCY's Baricitinib. That would be very positive news for INCY.
Well, positive. Lilly probably has resources to advance both if it was appropriate. The standard for effectiveness is high; bari meets it and tabal...was falling short.